Tumor necrosis factor (TNF) inhibitors revolutionalized therapy for both psoriasis and psoriatic arthritis. There are currently five marketed TNF inhibitors; infiiximab, eta-nercept, adalimumab, golimumab and certolizumab. TNF inhibitors clear psoriasis, control signs and symptoms of psoriatic arthritis, inhibit radiographic progression and improve quality of life in both psoriasis and psoriatic arthritis [1-11]. Some registry data suggest protection from cardiovascular morbidity and mortality although there is controversy in this area [12-14]. Much data exist from clinical trials, however there are fewer publications on the use in clinical practice. This supplement focuses on the use of infiiximab in clinical practice. Infiiximab is the only TNF blocker which is given intravenously and which has weight-based dosing.
展开▼
